Novel Intravaginal Ring as a Non-Hormonal Contraceptive Multipurpose Prevention Technology (MPT)
The Population Council and partners are advancing the development of a non-hormonal vaginal ring with potential to provide contraception along with broad microbial action against bacterial vaginosis-associated bacteria, HIV, HSV-2, chlamydia, and gonorrhea. This ring will also be designed with the added benefit of promoting vaginal health by helping to maintain optimal vaginal pH and reducing symptoms of bacterial vaginosis.
Pre-formulation, pre-Phase 1 Clinical Trials among end-users, Non-clinical
Delivery Route & Method:
Intravaginal - Intravaginal Ring (IVR)
Mechanism of Action:
These actives will have spermicidal activity and broad antibacterial/antiviral activity against chlamydia, gonorrhea, bacterial vaginosis, HSV-2, and HIV. The ring will also increase vaginal lactic acid concentrations that could further optimize vaginal health, providing a significant secondary benefit of reducing symptoms of bacterial vaginosis (BV).
- Population Council
- Queen's University Belfast
- Weill Cornell Medical College
- National Institutes of Health (NIH)
- Nat. Institute Child Health & Human Development (NICHD)
P50 Clinical Research Center Grant
- Bacterial Vaginosis (BV)